Stada Arzneimittel

ots Ad hoc-Service: STADA Arzneimittel AG STADA expects to boost expansion with biogenerics after having signed new agreements

Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. ---------------------------------------------------- Bad Vilbel (ots Ad hoc-Service) - STADA Arzneimittel AG, which is listed on Germanys S-DAX small-cap share index, has successfully concluded the negotiations it started last spring on the development of biotechnologically manufactured generics (biogenerics). These will give STADA access to one of the largest and fastest growing segments of the healthcare market, but for which generics are very costly to develop. BIOGENERICS Arzneimittel AG, founded by STADA, has increased its capital in a private placement managed by HSBC Trinkaus & Burkhardt. STADA continues to hold 10% of the capital in BIOGENERICS Arzneimittel AG, which has liquid funds of 65 million Euro available to finance the development of biogenerics. BIOGENERICS Arzneimittel AG has mandated DSM Biologics (having facilities in Montreal, Canada and Groningen, The Netherlands), a subsidiary of the Dutch DSM Group, to develop four biogenerics, namely Erythropoetin (Epoetin), Filgrastim, Interferon alpha-2b and Interferon beta-1a. The aggregate market volume of these products in the EU alone currently exceeds 1 billion Euro is growing at double-digit percentage rates every year. After the pharmaceutical approval, STADA and its subsidiaries have the rights to market these biogenerics worldwide. Once they have been launched on the market, BIOGENERICS Arzneimittel AG will receive sales- related licensing income from STADA for each biogeneric. STADA retains an option to repurchase all the shares in BIOGENERICS Arzneimittel AG as from 2010. The biogenerics will be produced by DSM Biologics. The four products are due to be gradually launched on the market from 2005. STADA expects these to provide a substantial boost to its expansion plans and believes that 3 years after having introduced all four products, these biogenerics can generate additional annual revenues in excess of 100 million Euro for the Group. Further information on STADA Arzneimittel AG and a detailed press release can be found on the internet at End ----------------------------------------------------- Internet: Original-Content von: Stada Arzneimittel, übermittelt durch news aktuell

Themen in dieser Meldung

Das könnte Sie auch interessieren: